Roles of PPARs in health and disease

In developed societies, chronic diseases such as diabetes, obesity, atherosclerosis and cancer are responsible for most deaths. These ailments have complex causes involving genetic, environmental and nutritional factors. There is evidence that a group of closely related nuclear receptors, called peroxisome proliferator-activated receptors (PPARs), may be involved in these diseases. This, together with the fact that PPAR activity can be modulated by drugs such as thiazolidinediones and fibrates, has instigated a huge research effort into PPARs. Here we present the latest developments in the PPAR field, with particular emphasis on the physiological function of PPARs during various nutritional states, and the possible role of PPARs in several chronic diseases.

[1]  D. Kelly,et al.  A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Sporn,et al.  A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. , 1999, Cancer research.

[3]  J. Auwerx,et al.  Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor-gamma in human adipocytes. , 1999, Diabetes.

[4]  K. Kinzler,et al.  PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.

[5]  G. Assmann,et al.  Phytanic Acid Activates the Peroxisome Proliferator-activated Receptor α (PPARα) in Sterol Carrier Protein 2-/ Sterol Carrier Protein x-deficient Mice* , 1999, The Journal of Biological Chemistry.

[6]  W. Wahli,et al.  Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. , 1999, The Journal of clinical investigation.

[7]  Frank J. Gonzalez,et al.  Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1* , 1999, The Journal of Biological Chemistry.

[8]  B. Spiegelman,et al.  Chemical Probes That Differentially Modulate Peroxisome Proliferator-activated Receptor α and BLTR, Nuclear and Cell Surface Receptors for Leukotriene B4 * , 1999, The Journal of Biological Chemistry.

[9]  J. Morrow,et al.  Cyclo-oxygenase-2-derived prostacyclin mediates embryo implantation in the mouse via PPARdelta. , 1999, Genes & development.

[10]  Satoshi Tanaka,et al.  PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance , 1999 .

[11]  C. Glass,et al.  Expression of the peroxisome proliferator-activated receptor � (PPAR�) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein , 1998 .

[12]  R. Unger,et al.  Novel Form of Lipolysis Induced by Leptin* , 1999, The Journal of Biological Chemistry.

[13]  T. Leff,et al.  Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma. , 1999, Diabetes.

[14]  B. Spiegelman,et al.  Regulation of Peroxisome Proliferator-Activated Receptor γ Expression by Adipocyte Differentiation and Determination Factor 1/Sterol Regulatory Element Binding Protein 1: Implications for Adipocyte Differentiation and Metabolism , 1999, Molecular and Cellular Biology.

[15]  B. Spiegelman,et al.  PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro , 1999 .

[16]  O. Pedersen,et al.  Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-γ2 (PPAR-γ2): divergent modulating effects on body mass index in obese and lean Caucasian men , 1999, Diabetologia.

[17]  B. Spiegelman,et al.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Foretz,et al.  Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  K. Kinzler,et al.  PPAR d Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999 .

[20]  M. Sporn,et al.  A New Ligand for the Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ), GW7845, Inhibits Rat Mammary Carcinogenesis , 1999 .

[21]  N. Noy,et al.  Ligand selectivity of the peroxisome proliferator-activated receptor alpha. , 1999, Biochemistry.

[22]  R. Thieringer,et al.  Activation of Peroxisome Proliferator-Activated Receptor γ Does Not Inhibit IL-6 or TNF-α Responses of Macrophages to Lipopolysaccharide In Vitro or In Vivo , 2000, The Journal of Immunology.

[23]  J. V. Vanden Heuvel,et al.  Conjugated linoleic acid is a potent naturally occurring ligand and activator of PPARalpha. , 1999, Journal of lipid research.

[24]  M. Laakso,et al.  Two polymorphisms in the peroxisome proliferator-activated receptor-gamma gene are associated with severe overweight among obese women. , 1999, The Journal of clinical endocrinology and metabolism.

[25]  B. Spiegelman,et al.  ADD1/SREBP-1c Is Required in the Activation of Hepatic Lipogenic Gene Expression by Glucose , 1999, Molecular and Cellular Biology.

[26]  K. Chien,et al.  PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development , 1999 .

[27]  J. Ribalta,et al.  Vitamin A is linked to the expression of the AI-CIII-AIV gene cluster in familial combined hyperlipidemia. , 1999, Journal of lipid research.

[28]  T. Kooistra,et al.  Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha. , 1999, Blood.

[29]  W. Wahli,et al.  Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting , 1999 .

[30]  W. Wahli,et al.  Peroxisome Proliferator-activated Receptor β Regulates Acyl-CoA Synthetase 2 in Reaggregated Rat Brain Cell Cultures* , 1999, The Journal of Biological Chemistry.

[31]  V. Colantuoni,et al.  Pro12Ala substitution in the peroxisome proliferator-activated receptor-gamma2 is not associated with type 2 diabetes. , 1999, Diabetes.

[32]  J. Gimble,et al.  Effect of Peroxisome Proliferator-Activated Receptor Alpha Activators on Tumor Necrosis Factor Expression in Mice during Endotoxemia , 1999, Infection and Immunity.

[33]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[34]  S. O’Rahilly,et al.  Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension , 1999, Nature.

[35]  R. Evans,et al.  PPAR gamma is required for placental, cardiac, and adipose tissue development. , 1999, Molecular cell.